Vertex Pharmaceuticals Inc (VRTX)
483.96
-10.65
(-2.15%)
USD |
NASDAQ |
Nov 14, 16:00
483.73
-0.23
(-0.05%)
After-Hours: 20:00
Vertex Pharmaceuticals Net Income (TTM): -479.80M for Sept. 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | -479.80M |
| June 30, 2024 | -489.90M |
| March 31, 2024 | 4.019B |
| December 31, 2023 | 3.620B |
| September 30, 2023 | 3.470B |
| June 30, 2023 | 3.365B |
| March 31, 2023 | 3.260B |
| December 31, 2022 | 3.322B |
| September 30, 2022 | 3.273B |
| June 30, 2022 | 3.195B |
| March 31, 2022 | 2.451B |
| December 31, 2021 | 2.342B |
| September 30, 2021 | 2.176B |
| June 30, 2021 | 1.992B |
| March 31, 2021 | 2.762B |
| December 31, 2020 | 2.712B |
| September 30, 2020 | 2.691B |
| June 30, 2020 | 2.081B |
| March 31, 2020 | 1.511B |
| December 31, 2019 | 1.177B |
| September 30, 2019 | 2.144B |
| June 30, 2019 | 2.215B |
| March 31, 2019 | 2.155B |
| December 31, 2018 | 2.097B |
| September 30, 2018 | 647.05M |
| Date | Value |
|---|---|
| June 30, 2018 | 415.36M |
| March 31, 2018 | 225.99M |
| December 31, 2017 | 263.48M |
| September 30, 2017 | 195.74M |
| June 30, 2017 | 259.86M |
| March 31, 2017 | 177.34M |
| December 31, 2016 | -112.05M |
| September 30, 2016 | -218.73M |
| June 30, 2016 | -275.04M |
| March 31, 2016 | -399.36M |
| December 31, 2015 | -556.33M |
| September 30, 2015 | -659.26M |
| June 30, 2015 | -734.17M |
| March 31, 2015 | -704.70M |
| December 31, 2014 | -738.56M |
| September 30, 2014 | -517.61M |
| June 30, 2014 | -471.69M |
| March 31, 2014 | -369.47M |
| December 31, 2013 | -445.03M |
| September 30, 2013 | -565.46M |
| June 30, 2013 | -498.87M |
| March 31, 2013 | -506.64M |
| December 31, 2012 | -107.03M |
| September 30, 2012 | 127.74M |
| June 30, 2012 | 406.40M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-489.90M
Minimum
Jun 2024
4.019B
Maximum
Mar 2024
2.422B
Average
2.701B
Median
Net Income (TTM) Benchmarks
| Eli Lilly and Co | 8.370B |
| Gilead Sciences Inc | 126.00M |
| Bristol-Myers Squibb Co | -7.258B |
| Moderna Inc | -2.224B |
| Sarepta Therapeutics Inc | 121.84M |